Tomaszewski, Joseph E.

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research

PARP inhibition in cancer therapyCancer therapeutics and mechanisms

Cited by 259

Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro

Erickson-Miller, C. L., May, R. D., Tomaszewski, J., Osborn, B., Murphy, M. J., Page, J. G., & Parchment, R. E. (1997) · Cancer Chemotherapy and Pharmacology

Cancer therapeutics and mechanismsImmunotoxicology and immune responses

Cited by 111

Lack of toxicity of a STAT3 decoy oligonucleotide

Sen, M., Tosca, P. J., Zwayer, C., Ryan, M. J., Johnson, J. D., Knostman, K. A. B., Giclas, P. C., Peggins, J. O., Tomaszewski, J. E., McMurray, T. P., et al. (2009) · Cancer Chemotherapy and Pharmacology

Cytokine Signaling Pathways and InteractionsRNA Interference and Gene Delivery

Cited by 53

Abstract 3616: Validation and fitness testing of a quantitative immunoassay for HIF1α in biopsy specimens

Park, S. R., Kinders, R. J., Khin, S., Hollingshead, M., Parchment, R. E., Tomaszewski, J. E., & Doroshow, J. H. (2012) · Cancer Research

Cancer, Hypoxia, and MetabolismClinical Laboratory Practices and Quality Control

Cited by 1